Reviva Pharmaceuticals Holdings (RVPH) Free Cash Flow (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Free Cash Flow of -$3.8 million for Q1 2026, up 34.44% sequentially from -$5.8 million in Q4 2025, and up 53.61% YoY from -$2.5 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Free Cash Flow (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Free Cash Flow for 9 years, with the latest figure at -$3.8 million in Q1 2026.
- Quarterly Free Cash Flow rose 53.61% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.2 million (up 32.69% YoY) and the FY2025 annual result came in at -$24.6 million, up 26.68% from the prior year.
- Free Cash Flow advanced to -$3.8 million in Q1 2026 per RVPH's latest filing, from -$5.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$3.8 million in Q1 2026 and troughed at -$11.7 million in Q1 2024.
- A 5-year average of -$6.4 million and a median of -$5.8 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2026: Free Cash Flow slumped 198.43% in 2022, then soared 53.61% in 2026.
- Over 5 years, Free Cash Flow stood at -$4.7 million in 2022, then tumbled by 89.24% to -$8.9 million in 2023, then dropped by 2.52% to -$9.1 million in 2024, then soared by 36.29% to -$5.8 million in 2025, then surged by 34.44% to -$3.8 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$3.8 million, -$5.8 million, and -$5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | -2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.12 Mn |
| Jun 30, 2026 | -2.12 Mn |
| Mar 31, 2026 | -3.80 Mn |
| Mar 31, 2026 | -3.80 Mn |
| Dec 31, 2025 | -5.80 Mn |
| Dec 31, 2025 | -5.80 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -9.10 Mn |
| Dec 31, 2024 | -9.10 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Mar 31, 2024 | -11.73 Mn |